Optimized Split Zeocin Selection System Enhances Monoclonal Antibody Productivity and Reduces High Mannose Levels in CHO Cells.

The limited variety of selection markers presents a challenge in the development and production of complex biologic therapeutics. Here, we developed and optimized a split zeocin selection system using a split bleomycin binding protein (BBP) to address these limitations. Two split bleomycin binding protein strategies (the N-terminal fragment paired with the heavy chain + the C-terminal fragment paired with the light chain (LC), or the reciprocal arrangement) were evaluated in multiple monoclonal antibodies. Our results demonstrate that the split zeocin system achieves comparable or higher titers than the conventional biantibiotic resistance system (blasticidin and zeocin) while significantly reducing high mannose levels. Notably, the use of separate open reading fragments driven by the SV40 promoter resulted in more efficient recovery of functional split BBP compared with internal ribosome entry site-driven systems. The increased LC gene copy number observed in the split system likely promotes excess light-chain expression, facilitating mAb assembly and improving glycan maturation. Further evaluation across key stages of cell line development─pool selection, single-cell cloning, 60-population doubling level stability studies, and bioreactor scale-up─validated the system's robustness, reproducibility, and scalability. These findings highlight the split zeocin system as a cost-effective and innovative approach for improving both the productivity and product quality in large-scale biopharmaceutical production.

• Publication year

  2025

• Venue

  ACS Synthetic Biology

• Publication date

  2025-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/acssynbio.5c00533PMID 41211953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Do-it-yourself instrument integration into an existing mammalian cell line development automation platform.

  2025cited by this paper
• Accurate structure prediction of biomolecular interactions with AlphaFold 3

  2024cited by this paper
• SiMPl‐GS: Advancing Cell Line Development via Synthetic Selection Marker for Next‐Generation Biopharmaceutical Production

  2024cited by this paper
• Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs

  2024cited by this paper
• Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing

  2024cited by this paper
• Benchmark Glycan Profile of Therapeutic Monoclonal Antibodies Produced by Mammalian Cell Expression Systems

  2023cited by this paper
• Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones

  2022cited by this paper
• Protein Splicing of Inteins: A Powerful Tool in Synthetic Biology

  2022cited by this paper
• Choice of selectable marker affects recombinant protein expression in cells and exosomes

  2021cited by this paper
• Development of a proline-based selection system for reliable genetic engineering in Chinese hamster ovary cells.

  2020cited by this paper
• Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody

  2020cited by this paper
• Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak

  2020cited by this paper
• The pharmacology and therapeutic applications of monoclonal antibodies

  2019cited by this paper
• Phleomycin complex - Coordination mode and in vitro cleavage of DNA.

  2019cited by this paper
• Split selectable markers

  2019cited by this paper
• Comprehensive characterization of glutamine synthetase-mediated selection for the establishment of recombinant CHO cells producing monoclonal antibodies

  2018cited by this paper
• Insights into Structural and Mechanistic Features of Viral IRES Elements

  2018cited by this paper
• A simple method to determine IgG light chain to heavy chain polypeptide ratios expressed by CHO cells

  2016cited by this paper
• The present state of the art in expression, production and characterization of monoclonal antibodies

  2016cited by this paper
• Impact of Using Different Promoters and Matrix Attachment Regions on Recombinant Protein Expression Level and Stability in Stably Transfected CHO Cells

  2015cited by this paper
• Inteins: Nature's Gift to Protein Chemists.

  2014cited by this paper
• Antibody Therapeutics in Cancer

  2013cited by this paper
• Control of IgG LC:HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability.

  2013cited by this paper
• Evaluating the influence of selection markers on obtaining selected pools and stable cell lines in human cells

  2013cited by this paper
• Mammalian cell protein expression for biopharmaceutical production.

  2012cited by this paper
• Cell line‐specific control of recombinant monoclonal antibody production by CHO cells

  2010cited by this paper
• Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter

  2010cited by this paper
• Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system.

  2010cited by this paper
• A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies

  2009cited by this paper
• On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells

  2008cited by this paper
• Application of protein-fragment complementation assays in cell biology.

  2007cited by this paper
• Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.

  2007cited by this paper
• Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

  2007cited by this paper
• Universal strategies in research and drug discovery based on protein-fragment complementation assays

  2007cited by this paper
• Engineering a Selectable Marker for Hyperthermophiles*

  2005cited by this paper
• Exploiting internal ribosome entry sites in gene therapy vector design.

  2004cited by this paper
• The 1.6-Å Crystal Structure of the Copper(II)-bound Bleomycin Complexed with the Bleomycin-binding Protein from Bleomycin-producing Streptomyces verticillus *

  2002cited by this paper
• Detection of protein-protein interactions by protein fragment complementation strategies.

  2000cited by this paper
• Antiparallel Leucine Zipper-Directed Protein Reassembly: Application to the Green Fluorescent Protein

  2000cited by this paper
• Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments.

  1998cited by this paper
• Crystal structure and site‐directed mutagenesis of a bleomycin resistance protein and their significance for drug sequestering.

  1994cited by this paper
• Bleomycin resistance conferred by a drug‐binding protein

  1988cited by this paper
• Phleomycin resistance as a dominant selectable marker in CHO cells

  1988cited by this paper
• Copper-dependent cleavage of DNA by bleomycin.

  1987cited by this paper

• No citing papers are available for this paper.